Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy

Lignende værker

• Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting
  af: Nakayama, Izuma, et al.
  Udgivet: (2020)
• Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research
  af: Takahari, Daisuke, et al.
  Udgivet: (2020)
• Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
  af: Yusuke Kitagawa, et al.
  Udgivet: (2020-04-01)
• Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
  af: Kitagawa, Yusuke, et al.
  Udgivet: (2020)
• Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake
  af: Osumi, Hiroki, et al.
  Udgivet: (2018)